Aptevo Therapeutics Inc. (APVO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aptevo Therapeutics Inc. (APVO) trades at $4.50 with AI Score 30/100 (Grade D). Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic candidates for cancer treatment. Market cap: $9.84M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026APVO stock analysis for 2026: Analysts have set a consensus price target of $378.00 for Aptevo Therapeutics Inc., suggesting 8300.0% upside from the current price of $4.50. The AI MoonshotScore is 30/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
APVO: 1/1 perspectives are bearish.
How is this calculated? →Aptevo Therapeutics Inc. (APVO) Healthcare & Pipeline Overview
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in immunotherapeutic candidates for cancer. Their lead candidate, APVO436, targets acute myelogenous leukemia and myelodysplastic syndrome. The company leverages its ADAPTIR platform to develop bispecific antibodies, positioning it within the competitive immuno-oncology landscape.
What Is the Investment Thesis for APVO?
Aptevo Therapeutics presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of APVO436, currently in Phase 1b trials for AML and MDS. Positive clinical data from this trial could significantly increase the company's valuation. Further potential lies in the advancement of preclinical candidates like ALG.APV-527 and APVO603. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding. The company's market capitalization is approximately $10 million as of May 10, 2026, reflecting the inherent uncertainties of its pipeline. The collaboration with Alligator Bioscience AB provides some validation of Aptevo's technology and pipeline. Investment hinges on a positive outlook for APVO436's clinical development and the potential of its ADAPTIR platform.
Based on FMP financials and quantitative analysis
APVO Key Highlights
- Aptevo's lead candidate, APVO436, is currently in Phase 1b clinical trials for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
- The company's preclinical pipeline includes ALG.APV-527, a bispecific ADAPTIR candidate targeting 4-1BB (CD137) and 5T4, a tumor antigen expressed in various cancers.
- Aptevo has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
- Aptevo's ADAPTIR-FLEX platform is being utilized to develop APVO442, a bispecific candidate designed to enhance drug delivery to PSMA-positive tumors for prostate cancer treatment.
- Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Who Are APVO's Competitors?
APVO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| XNCR Xencor, Inc. | $15.00 | +0.02% | $1.11B | — |
| IMGN ImmunoGen | $31.23 | +0.02% | $8.73B | 46 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are APVO's Key Strengths?
- Proprietary ADAPTIR platform for bispecific antibody development.
- Clinical-stage lead candidate APVO436 targeting AML and MDS.
- Collaboration with Alligator Bioscience AB.
- Experienced management team with expertise in immuno-oncology.
What Are APVO's Weaknesses?
- Limited financial resources compared to larger biotechnology companies.
- Dependence on the success of a limited number of clinical candidates.
- High risk of clinical trial failures.
- Potential challenges in manufacturing and scaling up production of bispecific antibodies.
What Could Drive APVO Stock Higher?
- APVO436 Phase 1b clinical trial data readout for AML and MDS (expected within 12-24 months).
- Initiation of clinical trials for ALG.APV-527 (expected within 2-3 years, pending preclinical data and regulatory approvals).
- Continued preclinical development of APVO603.
- Potential strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for APVO?
- Financial-distress signal — its Altman Z-Score of -22.80 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for APVO436 or other pipeline candidates.
- Regulatory hurdles and delays in clinical development.
- Limited financial resources and the need for additional funding.
- Competition from larger biotechnology and pharmaceutical companies.
- Changes in the healthcare landscape and reimbursement policies.
What Are the Growth Opportunities for APVO?
- APVO436 Clinical Advancement: The successful completion of Phase 1b clinical trials for APVO436 in AML and MDS represents a significant growth opportunity. Positive data could lead to further clinical development, potential partnerships, and eventual commercialization. The market for AML and MDS treatments is substantial, with a growing need for more effective therapies. Success in these indications could open doors to exploring APVO436 in other hematological malignancies. The timeline for this growth opportunity is dependent on clinical trial progress, with potential data readouts expected in the next 12-24 months.
- ALG.APV-527 Development: Advancing ALG.APV-527, the bispecific ADAPTIR candidate targeting 4-1BB (CD137) and 5T4, into clinical trials represents another key growth opportunity. 5T4 is a tumor antigen expressed in various cancers, making this candidate potentially applicable to a broad range of solid tumors. The collaboration with Alligator Bioscience AB provides additional resources and expertise for this program. The timeline for this growth opportunity is dependent on preclinical data and regulatory approvals, with potential clinical trial initiation in the next 2-3 years.
- APVO603 Preclinical Progress: Continued preclinical development of APVO603, the dual agonist bispecific antibody targeting 4-1BB and OX40, offers a longer-term growth opportunity. This candidate aims to stimulate two key immune co-stimulatory molecules, potentially enhancing anti-tumor immunity. Success in preclinical studies could lead to clinical trials and potential applications in various cancer types. The timeline for this growth opportunity is dependent on preclinical data and regulatory approvals, with potential clinical trial initiation in the next 3-4 years.
- ADAPTIR-FLEX Platform Expansion: Leveraging the ADAPTIR-FLEX platform to develop additional bispecific candidates represents a broader growth opportunity. This platform allows for the creation of modular bispecific antibodies with potential applications across a range of cancer types. Aptevo can explore new targets and indications, expanding its pipeline and diversifying its risk. The timeline for this growth opportunity is ongoing, with potential new candidate selection and development in the coming years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies represents a significant growth opportunity. These partnerships could provide funding, expertise, and access to larger markets. Aptevo's ADAPTIR platform and pipeline of candidates could be attractive to companies seeking to expand their immuno-oncology portfolios. The timeline for this growth opportunity is uncertain, but potential partnership discussions could occur at any time based on clinical data and market interest.
What Opportunities Does APVO Have?
- Successful clinical development and commercialization of APVO436.
- Expansion of the pipeline through internal development and strategic partnerships.
- Application of the ADAPTIR platform to new targets and indications.
- Potential for breakthrough therapies in areas of unmet medical need.
What Threats Does APVO Face?
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays in clinical development.
- Changes in the healthcare landscape and reimbursement policies.
- Potential for generic competition if APVO436 is successful.
What Are APVO's Competitive Advantages?
- Proprietary ADAPTIR platform for developing bispecific antibodies.
- Clinical-stage lead candidate APVO436 with potential for significant impact.
- Collaboration with Alligator Bioscience AB validates technology and provides resources.
- Pipeline of preclinical candidates targeting various cancer types.
What Does APVO Do?
Aptevo Therapeutics Inc., founded in 2016 and headquartered in Seattle, Washington, is a clinical-stage biotechnology company dedicated to developing novel immunotherapeutic candidates for various forms of cancer. The company's primary focus is on harnessing the power of the immune system to fight cancer through innovative bispecific antibody technology. Aptevo's lead clinical candidate, APVO436, is a bispecific T-cell engaging antibody currently in Phase 1b clinical trials for the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). This therapy aims to redirect T-cells to target and destroy cancer cells expressing specific antigens. In addition to APVO436, Aptevo has a pipeline of preclinical candidates, including ALG.APV-527, a bispecific ADAPTIR candidate targeting 4-1BB (CD137) and 5T4, a tumor antigen found in various cancers. APVO603, another preclinical asset, is a dual agonist bispecific antibody targeting 4-1BB and OX40. Aptevo is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform, designed to enhance the delivery of drugs to PSMA-positive tumors for prostate cancer treatment. The company has a collaboration and option agreement with Alligator Bioscience AB to co-develop ALG.APV-527, expanding its research and development capabilities. Aptevo's ADAPTIR platform allows for the creation of modular bispecific antibodies with potential applications across a range of cancer types.
What Products and Services Does APVO Offer?
- Develop immunotherapeutic candidates for cancer treatment.
- Focus on bispecific antibody technology.
- Advance APVO436 through clinical trials for AML and MDS.
- Develop preclinical candidates like ALG.APV-527 and APVO603.
- Utilize the ADAPTIR platform to create novel bispecific antibodies.
- Collaborate with Alligator Bioscience AB on ALG.APV-527 development.
- Enhance drug delivery to PSMA-positive tumors for prostate cancer treatment with APVO442.
How Does APVO Make Money?
- Develop and out-license or sell novel immunotherapeutic candidates.
- Generate revenue through collaborations and partnerships.
- Advance clinical candidates through clinical trials to increase value.
- Focus on bispecific antibody technology for targeted cancer treatment.
What Industry Does APVO Operate In?
Aptevo Therapeutics operates within the competitive biotechnology industry, specifically focusing on immuno-oncology. This field is characterized by rapid innovation and intense competition, with numerous companies developing novel therapies to harness the immune system to fight cancer. The market for cancer immunotherapies is substantial and growing, driven by the increasing incidence of cancer and the limitations of traditional treatments like chemotherapy and radiation. Key trends include the development of bispecific antibodies, CAR-T cell therapies, and immune checkpoint inhibitors. Aptevo's ADAPTIR platform positions it to develop bispecific antibodies, potentially offering advantages in terms of efficacy and safety compared to existing therapies. The success of Aptevo depends on its ability to differentiate its candidates and navigate the complex regulatory landscape.
Who Are APVO's Key Customers?
- Potentially pharmaceutical companies through licensing agreements.
- Future patients who may benefit from their cancer therapies.
- Collaborators like Alligator Bioscience AB.
Company Profile
Aptevo Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Marvin L. White. APVO has traded publicly since 2016.
Aptevo Therapeutics Inc. (APVO) Valuation Context
Valued at $9.84M, APVO is classified as a micro-cap stock. Relative to its peer group, APVO's quantitative score of 30/100 is below the peer average of 64/100.
F-Score 1/9Financial Health
Aptevo Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.80 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Aptevo Therapeutics Inc. revenue of about $7.5M for fiscal 2026, with EPS near $-23.35.
APVO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary ADAPTIR platform for bispecific antibody development.
- Clinical-stage lead candidate APVO436 targeting AML and MDS.
- Collaboration with Alligator Bioscience AB.
- Experienced management team with expertise in immuno-oncology.
Bear Case
- Limited financial resources compared to larger biotechnology companies.
- Dependence on the success of a limited number of clinical candidates.
- High risk of clinical trial failures.
- Potential challenges in manufacturing and scaling up production of bispecific antibodies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
APVO Latest News
-
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
accessnewswire.com · May 13, 2026
APVO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APVO.
Price Targets
Consensus target: $378.00
APVO MoonshotScore
What does this score mean?
The MoonshotScore rates APVO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Marvin L. White
CEO
Marvin L. White serves as the CEO of Aptevo Therapeutics Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on oncology drug development. Prior to joining Aptevo, he held leadership positions at various companies, where he was responsible for overseeing clinical trials, regulatory submissions, and commercialization strategies. He has a proven track record of successfully bringing new therapies to market. His expertise spans across multiple therapeutic areas, including hematology and oncology.
Track Record: Since becoming CEO of Aptevo, Marvin L. White has focused on advancing the company's lead clinical candidate, APVO436, through Phase 1b clinical trials. He has also overseen the expansion of the company's preclinical pipeline and the establishment of strategic partnerships, such as the collaboration with Alligator Bioscience AB. Under his leadership, Aptevo has made progress in developing its ADAPTIR platform and exploring new applications for bispecific antibody technology.
APVO Healthcare Stock FAQ
What does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic candidates for the treatment of various forms of cancer. The company's core technology is its ADAPTIR platform, which allows for the creation of bispecific antibodies designed to target and destroy cancer cells. Aptevo's lead candidate, APVO436, is currently in Phase 1b clinical trials for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The company also has a pipeline of preclinical candidates targeting other cancer types. Aptevo aims to improve cancer treatment outcomes by harnessing the power of the immune system.
What do analysts say about APVO stock?
As of May 10, 2026, analyst coverage of Aptevo Therapeutics Inc. (APVO) is limited, reflecting its small market capitalization and early stage of development. Given the inherent risks associated with clinical-stage biotechnology companies, analyst ratings and price targets can be highly volatile and subject to change based on clinical trial results and regulatory developments. Investors should conduct their own thorough research and consider the company's financial position, pipeline progress, and competitive landscape before making any investment decisions. The company's future success hinges on the successful development and commercialization of its immunotherapeutic candidates.
What are the main risks for APVO?
Aptevo Therapeutics faces several key risks inherent to clinical-stage biotechnology companies. These include the risk of clinical trial failures, which could significantly impact the company's valuation and future prospects. The company also faces regulatory risks associated with obtaining approval for its drug candidates. Financial risk is another significant concern, as Aptevo relies on external funding to support its research and development activities. Competition from larger biotechnology and pharmaceutical companies with greater resources is also a major challenge. Additionally, changes in the healthcare landscape and reimbursement policies could affect the commercial potential of Aptevo's therapies.
What is Aptevo Therapeutics Inc.'s drug pipeline status?
Aptevo Therapeutics' drug pipeline is focused on immunotherapeutic candidates for cancer treatment. The lead candidate, APVO436, is in Phase 1b clinical trials for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Preclinical candidates include ALG.APV-527, targeting 4-1BB (CD137) and 5T4, and APVO603, a dual agonist bispecific antibody targeting 4-1BB and OX40. APVO442 is being developed using the ADAPTIR-FLEX platform to enhance drug delivery to PSMA-positive tumors for prostate cancer. Upcoming catalysts include data readouts from the APVO436 Phase 1b trial and potential clinical trial initiation for ALG.APV-527, pending preclinical data and regulatory approvals.
How does Aptevo Therapeutics Inc. plan to fund its operations?
As a clinical-stage biotechnology company, Aptevo Therapeutics relies on a combination of funding sources to support its operations. These sources typically include equity financing through public or private offerings, debt financing, and revenue generated through collaborations and partnerships. Given the high costs associated with clinical trials and drug development, Aptevo will likely need to raise additional capital in the future to advance its pipeline candidates. The company's ability to secure funding will depend on its clinical progress, market conditions, and investor sentiment. Strategic partnerships with larger pharmaceutical companies could also provide a significant source of funding.
What are the key factors to evaluate for APVO?
Aptevo Therapeutics Inc. (APVO) holds an AI score of 30/100 (low). Analysts target $378.00 (+8300%). Not financial advice.
How frequently does APVO data refresh on this page?
APVO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven APVO's recent stock price performance?
Aptevo Therapeutics Inc. (APVO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary ADAPTIR platform for bispecific antibody development. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.